How is SARS-CoV-2 COVID-19 Vaccine mRNA-LNP Spike Protein Pfizer Intramuscular Route dosed?
The SARS-CoV-2 (COVID-19) Vaccine, mRNA-LNP, Spike Protein (Pfizer) is dosed intramuscularly. The primary series is usually given in two doses, with a minimum interval of three weeks between doses. Patients with weakened immune systems may receive a third dose at least 28 days after the first two doses. For vaccines supplied in vials with orange caps, the vaccine is typically given to patients aged 5 to 11 years old. The first booster dose is administered at least 5 months after the primary series, and it is usually given to patients aged 5 years and older. A first booster dose may also be given to patients aged 18 years and older who have received primary vaccination with another authorized or approved COVID-19 vaccine.
What is the dosage form of SARS-CoV-2 COVID-19 Vaccine mRNA-LNP Spike Protein Pfizer Intramuscular Route?
The SARS-CoV-2 (COVID-19) Vaccine, mRNA-LNP, Spike Protein (Pfizer) is available in the following dosage form: Suspension.
How is SARS-CoV-2 COVID-19 Vaccine mRNA-LNP Spike Protein Pfizer Intramuscular Route administered?
The SARS-CoV-2 (COVID-19) Vaccine, mRNA-LNP, Spike Protein (Pfizer) is administered intramuscularly. The vaccine is given only by or under the direct supervision of a healthcare professional. The primary series for this vaccine is typically given in two doses, with at least three weeks between each dose. For patients with a weak immune system, a third dose may be given at least 28 days after the first two doses. The vaccine is available in suspension form.
What are common precautions when taking SARS-CoV-2 COVID-19 Vaccine mRNA-LNP Spike Protein Pfizer Intramuscular Route?
Common precautions when taking SARS-CoV-2 (COVID-19) Vaccine, mRNA-LNP, Spike Protein (Pfizer) intramuscular route include:
- Informing your doctor about any allergies or unusual reactions to this medicine or other medicines.
- Reporting any side effects to your healthcare professional, such as pain, redness, or swelling at the injection site, dizziness, or fainting.
- Being observed for a short period after receiving the vaccine to manage fainting or feeling faint.
- Being cautious if you have a weakened immune system or are 50 years of age or older and receiving a second booster dose of the vaccine. Please note that the Monovalent Pfizer-BioNTech COVID-19 vaccine is no longer authorized for use in the United States. Always consult with your healthcare professional for personalized advice and follow the information provided in the Fact Sheet for Recipients and Caregivers carefully.